Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer
- PMID: 9743058
- DOI: 10.1097/00007611-199809000-00010
Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer
Abstract
Objectives: We sought to determine the prevalence of hot flushes after neoadjuvant hormonal therapy.
Methods: Forty-three patients who received neoadjuvant hormonal therapy before radical prostatectomy were asked to complete a questionnaire regarding hot flushes.
Results: Complete information was available for 35 of the 43 patients. No hot flushes were noted in 20%; in 69%, hot flushes were noted during treatment but resolved after termination of treatment; and in 11%, hot flushes continued for at least 3 months after cessation of hormonal therapy. Analyzing the data with respect to duration of hormonal therapy showed that patients receiving neoadjuvant hormonal therapy for more than 4 months had the highest incidence of persistent hot flushes.
Conclusions: Hot flushes will be noted in 80% of patients who receive neoadjuvant hormonal therapy. In approximately 10%, hot flushes will continue for a significant period after hormonal therapy is terminated. Patients should be apprised of this potential side effect.
Similar articles
-
Transdermal estrogen in the treatment of hot flushes in men with prostate cancer.Urology. 2000 Jan;55(1):97-101. doi: 10.1016/s0090-4295(99)00370-2. Urology. 2000. PMID: 10654902 Clinical Trial.
-
Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.Psychooncology. 2009 Jun;18(6):598-605. doi: 10.1002/pon.1427. Psychooncology. 2009. PMID: 18942660
-
Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.J Urol. 1999 Sep;162(3 Pt 1):753-7. doi: 10.1097/00005392-199909010-00035. J Urol. 1999. PMID: 10458359 Clinical Trial.
-
[Clinical evaluation of hot flushes developing during endocrine therapy for prostate carcinoma].Nihon Hinyokika Gakkai Zasshi. 2003 Sep;94(6):614-20. doi: 10.5980/jpnjurol1989.94.614. Nihon Hinyokika Gakkai Zasshi. 2003. PMID: 14531271 Review. Japanese.
-
Complications of androgen-deprivation therapy for prostate cancer.Clin Prostate Cancer. 2003 Dec;2(3):147-52. doi: 10.3816/cgc.2003.n.022. Clin Prostate Cancer. 2003. PMID: 15040857 Review.
Cited by
-
Management of hot flashes in breast cancer survivors and men with prostate cancer.Curr Oncol Rep. 2004 Jul;6(4):285-90. doi: 10.1007/s11912-004-0037-y. Curr Oncol Rep. 2004. PMID: 15161582 Review.
-
National survey addressing the information needs of primary care physicians: Side effect management of patients on androgen deprivation therapy.Can Urol Assoc J. 2014 Mar;8(3-4):E227-34. doi: 10.5489/cuaj.1015. Can Urol Assoc J. 2014. PMID: 24839488 Free PMC article.
-
Management of complications of androgen deprivation therapy in the older man.Crit Rev Oncol Hematol. 2009 Jun;70(3):235-55. doi: 10.1016/j.critrevonc.2008.09.004. Epub 2008 Oct 25. Crit Rev Oncol Hematol. 2009. PMID: 18952456 Free PMC article. Review.
-
Optimal delivery of male breast cancer follow-up care: improving outcomes.Breast Cancer (Dove Med Press). 2015 Nov 23;7:371-9. doi: 10.2147/BCTT.S75630. eCollection 2015. Breast Cancer (Dove Med Press). 2015. PMID: 26648754 Free PMC article. Review.
-
Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB.J Support Oncol. 2010 May-Jun;8(3):128-32. J Support Oncol. 2010. PMID: 20552926 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical